These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 20210753)

  • 1. CDK inhibitors: from the bench to clinical trials.
    Rizzolio F; Tuccinardi T; Caligiuri I; Lucchetti C; Giordano A
    Curr Drug Targets; 2010 Mar; 11(3):279-90. PubMed ID: 20210753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer therapeutic strategies based on CDK inhibitors.
    Esposito L; Indovina P; Magnotti F; Conti D; Giordano A
    Curr Pharm Des; 2013; 19(30):5327-32. PubMed ID: 23394082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel small molecule cyclin-dependent kinases modulators in human clinical trials.
    Senderowicz AM
    Cancer Biol Ther; 2003; 2(4 Suppl 1):S84-95. PubMed ID: 14508085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDK inhibitors in cancer therapy: what is next?
    Malumbres M; Pevarello P; Barbacid M; Bischoff JR
    Trends Pharmacol Sci; 2008 Jan; 29(1):16-21. PubMed ID: 18054800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
    Grant S; Roberts JD
    Drug Resist Updat; 2003 Feb; 6(1):15-26. PubMed ID: 12654284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early development of cyclin dependent kinase modulators.
    Roy KK; Sausville EA
    Curr Pharm Des; 2001 Nov; 7(16):1669-87. PubMed ID: 11562305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
    Senderowicz AM
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin-dependent kinase inhibitors as anticancer drugs.
    Krystof V; Uldrijan S
    Curr Drug Targets; 2010 Mar; 11(3):291-302. PubMed ID: 20210754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.
    Senderowicz AM
    Cancer Chemother Biol Response Modif; 2001; 19():165-88. PubMed ID: 11686013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ATP-noncompetitive CDK inhibitors for cancer therapy: an overview.
    Abate AA; Pentimalli F; Esposito L; Giordano A
    Expert Opin Investig Drugs; 2013 Jul; 22(7):895-906. PubMed ID: 23735075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer.
    Vermeulen K; Van Bockstaele DR; Berneman ZN
    Cell Prolif; 2003 Jun; 36(3):131-49. PubMed ID: 12814430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin-dependent kinases as new targets for the prevention and treatment of cancer.
    Senderowicz AM
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1229-53. PubMed ID: 12512390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preclinical and clinical development of cyclin-dependent kinase modulators.
    Senderowicz AM; Sausville EA
    J Natl Cancer Inst; 2000 Mar; 92(5):376-87. PubMed ID: 10699068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATP-noncompetitive inhibitors of CDK-cyclin complexes.
    Orzáez M; Gortat A; Mondragón L; Bachs O; Pérez-Payá E
    ChemMedChem; 2009 Jan; 4(1):19-24. PubMed ID: 19039815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclin-dependent kinases as targets for cancer therapy.
    Senderowicz AM
    Cancer Chemother Biol Response Modif; 2002; 20():169-96. PubMed ID: 12703205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of cyclin-dependent kinases - a review of the recent patent literature.
    Basso AD; Doll RJ
    Recent Pat Anticancer Drug Discov; 2006 Nov; 1(3):357-67. PubMed ID: 18221046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDK inhibitors in clinical development for the treatment of cancer.
    Fischer PM; Gianella-Borradori A
    Expert Opin Investig Drugs; 2003 Jun; 12(6):955-70. PubMed ID: 12783600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin-dependent kinase inhibitors.
    Dai Y; Grant S
    Curr Opin Pharmacol; 2003 Aug; 3(4):362-70. PubMed ID: 12901944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cell cycle as a target for cancer therapy: basic and clinical findings with the small molecule inhibitors flavopiridol and UCN-01.
    Senderowicz AM
    Oncologist; 2002; 7 Suppl 3():12-9. PubMed ID: 12165651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.